Bill & Melinda Gates Foundation Trust’s Latest Bet on China & Two Other Latest Hedge Fund Moves

In another filing, Kevin Kotler‘s Broadfin Capital reported a 6.11% stake in Nexvet Biopharma plc (NASDAQ:NVET), which contains 700,000 shares. Nexvet is a $46 million clinical-stage biopharmaceutical company that develops therapies for pets. The stock is down by 56% since it started trading on NASDAQ at the beginning of February. The company has recently announced a successful pivotal safety and efficacy study of its NV-01, which is a monoclonal antibody therapy for the control of pain from osteoarthritis in dogs. The study met is primary endpoint and Nexvet Biopharma plc (NASDAQ:NVET) plans to use the data in submissions for marketing authorizations in Europe and the US. Aside from Broadfin, three other funds among those we follow reported long positions in Nexvet as of the end of September. One of the company’s largest shareholders is Farallon Capital Management, which reported ownership of some 2.50 million shares in its latest 13F.

Finally, Noah Levy and Eugene Dozortsev‘s Newtyn Management have disclosed a new position in CSW Industrials Inc (NASDAQ:CSWI), a $580 million diversified industrial company that is engaged in the manufacturing and sale of coatings, sealants, and specialty chemicals. According to the recently-filed 13G, Newtyn owns nearly 1.18 million shares of CSW Industrials Inc (NASDAQ:CSWI), which represent 7.6% of the company’s outstanding stock. CSW Industrials was spun off from Capital Southwest in September and shareholders have received shares following the distribution. Newtyn owned 282,477 shares of Capital Southwest at the end of September, alongside 10 other funds from our database that held shares of the company. The shares of CSW Industrials Inc (NASDAQ:CSWI) have appreciated by around 23% since they started trading and are currently trading at around 17.8 times earnings, slightly below the S&P 500 average.

Disclosure: none